pI: 4.2855 |
Length (AA): 181 |
MW (Da): 18441 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
24 | 177 | 3rfq (A) | 24 | 177 | 96.00 | 0 | 1 | 2.11913 | -2.19 |
24 | 181 | 3tcr (A) | 21 | 178 | 79.00 | 0 | 1 | 1.94303 | -1.85 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Dormant phase. | murphy |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Dormant phase. | hasan |
murphy | Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. |
hasan | Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. |
Ortholog group members (OG5_130343)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_09705 | Probable molybdopterin binding domain containing protein |
Caenorhabditis elegans | CELE_W01A11.6 | Protein MOC-2 |
Escherichia coli | b0782 | inactive molybdopterin adenylyltransferase |
Escherichia coli | b0009 | molybdochelatase incorporating molybdenum into molybdopterin |
Loa Loa (eye worm) | LOAG_13272 | hypothetical protein |
Mycobacterium leprae | ML0177 | Possible pterin-4-alpha-carbinolamine dehydratase MoaB2 (4-alpha-hydroxy-tetrahydropterin dehydratase) (pterin-4-A-carbinolamine |
Mycobacterium tuberculosis | Rv0984 | Possible pterin-4-alpha-carbinolamine dehydratase MoaB2 (PHS) (4-alpha- hydroxy-tetrahydropterin dehydratase) (pterin-4-a-carbin |
Mycobacterium tuberculosis | Rv0865 | Probable molybdopterin biosynthesis Mog protein |
Mycobacterium ulcerans | MUL_0285 | molybdopterin biosynthesis Mog protein |
Mycobacterium ulcerans | MUL_4698 | pterin-4-alpha-carbinolamine dehydratase MoaB2 |
Schistosoma mansoni | Smp_158680 | molybdopterin biosynthesis protein |
Schmidtea mediterranea | mk4.049131.00 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu1000 this record | Mycobacterium tuberculosis | non-essential | nmpdr |
mtu881 | Mycobacterium tuberculosis | non-essential | nmpdr |
b0009 | Escherichia coli | non-essential | goodall |
b0782 | Escherichia coli | non-essential | goodall |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.